Idiopathic pulmonary fibrosis (IPF) is a rare, sporadic, and fatal interstitial lung disease. As the morbidity and mortality rates associated with IPF remain high, prompt idiopathic pulmonary fibrosis treatment is critical to safeguard individuals’ lung function, reduce the risk of acute exacerbations, and improve outcomes.
According to the National Institutes of Health (NIH), idiopathic pulmonary fibrosis affects approximately 100,000 people in the United States. Every year, between 30,000 and 40,000 new cases are diagnosed. Idiopathic pulmonary fibrosis affects 13 to 20 people out of every 100,000 people worldwide
As per DelveInsight’s latest published Idiopat...
